B. Mercorelli

发表

Antiviral strategies against influenza virus: towards new therapeutic approaches

G. Palù, A. Loregian, C. Compagnin, 2014, Cellular and Molecular Life Sciences.

The Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 Is Modified by SUMO in a DNA-Dependent Manner

G. Alvisi, H. Urlaub, G. Palù, 2012, PloS one.

Role of Homodimerization of Human Cytomegalovirus DNA Polymerase Accessory Protein UL44 in Origin-Dependent DNA Replication in Cells

G. Alvisi, G. Palù, A. Loregian, 2008, Journal of Virology.

Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanism

G. Palù, A. Loregian, D. Coen, 2007, Nucleic acids research.

Sulfated Derivatives of Escherichia coli K5 Capsular Polysaccharide Are Potent Inhibitors of Human Cytomegalovirus

G. Palù, A. Loregian, D. Lembo, 2010, Antimicrobial Agents and Chemotherapy.

A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.

F. Spyrakis, L. Goracci, G. Cruciani, 2019, Cancer letters.

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization

Lydia Siragusa, L. Goracci, G. Cruciani, 2022, Antiviral Research.

Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.

L. Goracci, G. Cruciani, G. Palù, 2014, Journal of medicinal chemistry.

A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.

L. Goracci, G. Cruciani, G. Palù, 2015, Journal of medicinal chemistry.

Divide et impera: An In Silico Screening Targeting HCMV ppUL44 Processivity Factor Homodimerization Identifies Small Molecules Inhibiting Viral Replication

G. Alvisi, G. Palù, A. Loregian, 2020, Viruses.

Divide et Impera: Identification of Small-Molecule Inhibitors of HCMV Replication Interfering with Dimerization of DNA Polymerase Processivity Factor UL44

G. Alvisi, G. Palù, A. Loregian, 2020, bioRxiv.

A Point Mutation in a Herpesvirus Polymerase Determines Neuropathogenicity

G. Palù, A. Loregian, N. Osterrieder, 2007, PLoS pathogens.

A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells

G. Palù, A. Loregian, B. Mercorelli, 2018, Scientific Reports.

Approaches for the generation of new anti-cytomegalovirus agents: identification of protein-protein interaction inhibitors and compounds against the HCMV IE2 protein.

G. Palù, A. Loregian, G. Gribaudo, 2014, Methods in molecular biology.

4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.

I. D. de Esch, C. Tintori, A. L. Fallacara, 2016, Journal of medicinal chemistry.

Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediate‐Early 2 Protein, a Promising Target for Anti‐HCMV Treatment

C. Pannecouque, G. Palù, A. Loregian, 2013, ChemMedChem.

Human cytomegalovirus DNA replication: antiviral targets and drugs

G. Palù, A. Loregian, B. Mercorelli, 2008, Reviews in medical virology.

The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus That Are Essential for Viral Replication

G. Palù, A. Loregian, A. Luganini, 2014, Antimicrobial Agents and Chemotherapy.

The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein

B. Gatto, M. Palumbo, G. Palù, 2010, Antimicrobial Agents and Chemotherapy.

A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity

G. Palù, A. Loregian, B. Mercorelli, 2008, Antimicrobial Agents and Chemotherapy.

Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives

G. Palù, A. Loregian, D. Lembo, 2011, Pharmacology & Therapeutics.

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs.

A. Loregian, A. Luganini, G. Gribaudo, 2021, Antiviral research.

Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.

L. Goracci, G. Cruciani, G. Palù, 2013, Journal of medicinal chemistry.

Drug Repurposing for Viral Infectious Diseases: How Far Are We?

G. Palù, A. Loregian, B. Mercorelli, 2018, Trends in Microbiology.

Explorer Human Cytomegalovirus Inhibitor AL 18 Also Possesses Activity against Influenza A and B Viruses

L. Goracci, G. Cruciani, G. Palù, 2017 .

Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses

L. Goracci, G. Cruciani, G. Palù, 2012, Antimicrobial Agents and Chemotherapy.

Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication.

G. Palù, A. Loregian, A. Luganini, 2016, Cell chemical biology.

The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early‐2 (IE2) protein transactivating activity.

G. Palù, A. Loregian, A. Luganini, 2019, Antiviral research.

Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”

G. Palù, A. Loregian, A. Luganini, 2019, Viruses.

Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate‐Early 2 (IE2) protein

G. Palù, A. Loregian, A. Luganini, 2018, Antiviral research.

The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication

G. Palù, A. Loregian, A. Luganini, 2020, Antimicrobial Agents and Chemotherapy.

Small-Molecule Inhibitor of Flaviviral NS3-NS5 Interaction with Broad-Spectrum Activity and Efficacy In Vivo

M. Sturlese, S. Moro, A. Loregian, 2023, mBio.

The Dimeric Form of HPV16 E6 Is Crucial to Drive YAP/TAZ Upregulation through the Targeting of hScrib

G. Alvisi, L. Banks, G. Palù, 2021, Cancers.

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells

A. Loregian, B. Mercorelli, Chiara Bertagnin, 2021, Cancers.

Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase

Giorgio Palù, Gabriele Cruciani, Laura Goracci, 2012, Proceedings of the National Academy of Sciences.

Indomethacin-based PROTACs as pan-coronavirus antiviral agents

Lydia Siragusa, L. Goracci, G. Cruciani, 2021, European Journal of Medicinal Chemistry.

Potent and broad‐spectrum cycloheptathiophene‐3‐carboxamide compounds that target the PA‐PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance

G. Palù, A. Loregian, B. Mercorelli, 2019, Antiviral research.

A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells

G. Palù, A. Loregian, B. Mercorelli, 2018, Scientific Reports.

A small molecule targeting the interaction between human papillomavirus E7 oncoprotein and cellular phosphatase PTPN14 exerts antitumoral activity in cervical cancer cells.

M. Sturlese, A. Loregian, B. Mercorelli, 2023, Cancer Letters.